Evidence map›Paper›PMID 37004644›Full record

ArticleInvestigational new drugs2023

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.

Christopher N Nguyen, Swaminathan P Iyer, Madeleine Duvic, Prajak J Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O Huen

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Christopher N NguyenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Christopher.Nguyen42@gmail.com.
Swaminathan P IyerDepartment of Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Madeleine DuvicDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prajak J BardeRhizen Pharmaceuticals AG, Basel, Switzerland.
Ajit NairRhizen Pharmaceuticals AG, Basel, Switzerland.
Kasi Viswanath RouthuRhizen Pharmaceuticals AG, Basel, Switzerland.
Auris O HuenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USRhizen Pharmaceuticals (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.

Indexed as

Lymphoma, T-Cell, CutaneousSezary SyndromeSkin NeoplasmsBenzopyransDepsipeptidesHumansPhosphatidylinositol 3-KinasesPurinesBenzopyransDepsipeptidesPhosphatidylinositol 3-KinasesPurinesromidepsintenalisibCutaneous T Cell LymphomaMycosis FungoidesRefractorySézary Syndrome

Identifiers

PMID37004644
OpenAlexW4362505731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.